Evidence map›Paper›PMID 30730295›Full record

ArticleJMIR research protocols2019

Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review.

Edward Meinert, Abrar Alturkistani, Tasnime Osama, Celine-Lea Halioua-Haubold, Josip Car, Azeem Majeed, Glenn Wells, Robert E MacLaren, David Brindley

Abstract read
In one paragraph

Article in JMIR research protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Edward MeinertGlobal Digital Health Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0003-2484-3347
Abrar AlturkistaniGlobal Digital Health Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0001-7935-8870
Tasnime OsamaGlobal Digital Health Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0001-7349-8944
Celine-Lea Halioua-HauboldClinical Ophthalmology Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0001-5361-651X
Josip CarGlobal Digital Health Unit, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0001-8969-371X
Azeem MajeedDepartment of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0002-2357-9858
Glenn WellsOxford Academic Health Science Centre, Oxford, United Kingdom.ORCID http://orcid.org/0000-0003-3373-584X
Robert E MacLarenClinical Ophthalmology Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-3096-4682
David BrindleyHealthcare Translation Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-5166-8583

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPharmacogenomics suggests that diseases with similar symptomatic presentations often have varying genetic causes, affecting an individual patient's response to a specific therapeutic strategy. Gene therapies and somatic cell therapies offer unique therapeutic pathways for ocular diseases and often depend on increased understanding of the genotype-phenotype relationship in disease presentation and progression. While demand for personalized medicine is increasing and the required molecular tools are available, its adoption within pediatric ophthalmology remains to be maximized in the postgenomic era.

objectiveThe objective of our study was to address the individual hurdles encountered in the field of genomic-related clinical trials and facilitate the uptake of personalized medicine, we propose to conduct a review that will examine and identify the digital technologies used to facilitate data analysis in somatic and gene therapy trials in pediatric patients with ocular diseases.

methodsThis paper aims to present an outline for Healthcare Information Technology and Information and Communication Technology resources used in somatic and gene therapy clinical trials in children with ocular diseases. This review will enable authors to identify challenges and provide recommendations, facilitating the uptake of genetic and somatic therapies as therapeutic tools in pediatric ophthalmology. The review will also determine whether conducting a systematic review will be beneficial.

resultsDatabase searches will be initiated in September 2018. We expect to complete the review in December 2019.

conclusionsBased on review findings, the authors will summarize methods used for facilitating IT integration in personalized medicine. Additionally, it will identify further research gaps and determine whether conducting further reviews will be beneficial. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/10705.

Indexed as

clinical trialgene therapygenomicshealth carepersonalized medicine

Identifiers

PMID30730295
PMCPMC6383115

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.